TLN Järvinen, H Sievänen, P Kannus, J Jokihaara… - BMJ, 2011 - bmj.com Recently, van Staa and colleagues assessed the external validity of published cost effectiveness studies of selective cyclo-oxygenase-2 (COX 2) inhibitors by comparing the data used in these studies (typically from randomised trials) with observed clinical data.2 The trial data ... Cited by 5 - Related articles - All 4 versions
M Elam, LC Lovato… - Current Opinion in Lipidology, 2011 - journals.lww.com Purpose of review: To examine the results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid trial, particularly the subgroup analyses. It is important, when a study fails to meet its overall primary endpoint, to ensure that interpretation of the results include ... Cited by 2 - Related articles - All 4 versions
JQ Trojanowski… - Progress in neurobiology, 2011 - ncbi.nlm.nih.gov 1. Prog Neurobiol. 2011 Jul 23. [Epub ahead of print] Neurodegenerative disease biomarkers: Guideposts for diseaseprevention through early diagnosis and intervention. Trojanowski JQ, Hampel H. Department of Pathology ...
[HTML] from aphapublications.orgBA Ormond, BC Spillman… - … journal of public …, 2011 - ajph.aphapublications.org Barbara A. Ormond, Brenda C. Spillman, and Timothy A. Waidmann are with the Health Policy Center at The Urban Institute, Washington, DC. At the time of the study, Kyle J. Caswell was with the Health Policy Center at The Urban Institute and American University, Washington, DC. ... Cited by 3 - Related articles - All 8 versions
KC Dabhadkar, A Kulshreshtha, MK Ali… - Annu. Rev. Public …, 2011 - papers.ssrn.com Abstract: Cardiovascular diseases (CVD) account for one-third of annual global mortality. The aggregated benefits of concurrently controlling common CVD risk factors, such as dyslipidemia and hypertension, in people at overall risk for CVD is postulated to be more efficient than ... Cited by 2 - Related articles - All 2 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
